Brexidol Medicated Patch 14 Mg Joint Pain 4 Pieces

Therapeutic indications

BREXIDOL is indicated for the treatment of painful and inflammatory conditions of a rheumatic and traumatic nature of the joints, muscles, tendons and ligaments.

Dosage

It is recommended to use only one medicated plaster at a time and replace it every 24 hours for a period not exceeding 8 days. Do not apply two patches in the same day. BREXIDOL is to be used exclusively on intact skin. After having carefully washed and dried the painful area, rub one of the corners of BREXIDOL between your fingers to remove the protective film and apply the adhesive part directly on the skin. In the event that BREXIDOL must be applied to joints with greater mobility, such as the elbow or knee, it is advisable to use a retention bandage to be applied to the flexed joint, in order to keep the patch in place. Do not exceed the recommended doses.

Overdose

There are no known cases of overdose. In the event of an overdose with evident clinical manifestations, immediately institute symptomatic therapy and apply common emergency measures as appropriate.

Contraindications

Hypersensitivity to the active substance (piroxicam) or to any of the excipients. Patients in whom substances with a similar mechanism of action (NSAIDs) have caused hypersensitivity reactions (see section 4.4). BREXIDOL is contraindicated in patients with active peptic ulcer, patients with bronchial asthma, a history of gastrointestinal haemorrhage from NSAIDs. Patients on anticoagulant therapy. Pregnancy and lactation (see section 4.6). Children under the age of 12. BREXIDOL patch should not be used on open wounds or lesions, but only on intact skin. Avoid contact with eyes and mucous membranes.

Side effects

The use of the product can cause local skin reactions of an irritative or allergic type such as erythema, itching, burning, contact dermatitis, numbness and tingling at the application site; cases of extensive and severe dermatological lesions such as urticaria, Quincke's edema, erythema multiforme have been reported with this type of medicinal products.More extensive and more severe photosensitivity reactions and skin and mucosal reactions, including asthma attacks, are possible. Systemic undesirable reactions following the topical use of piroxicam are unlikely; since the plasma levels obtained are lower than those measured after systemic administration but very variable from individual to individual, it is not possible to exclude, especially in the case of therapies prolonged beyond the recommended term and the non-observance of contraindications and warnings, the appearance of undesirable effects systemic, especially gastrointestinal (see sections 4.4 and 5.2). Any appearance of general or application site side effects requires discontinuation of therapy.

Pregnancy and breastfeeding

Brexidol is contraindicated during pregnancy and breastfeeding and is not recommended for women planning to become pregnant. Administration should be discontinued in women with fertility problems or who are undergoing fertility investigations.

Special warnings

The serum levels achieved with BREXIDOL were significantly lower than those obtained by oral administration but with a strong individual variability for which the onset of systemic undesirable effects, especially at the gastrointestinal level, cannot be excluded. Analgesics, antipyretics, non-steroidal anti-inflammatory drugs, including piroxicam, can cause hypersensitivity reactions, potentially serious even in subjects not previously exposed to this type of drug. These include asthma attacks, skin rashes, allergic rhinitis and anaphylactic-type reactions. BREXIDOL should be used with caution in subjects with chronic obstructive diseases of the bronchi, allergic rhinitis or inflammation of the nasal mucosa (nasal polyps) in which asthma attacks or localized inflammatory reactions of the skin and mucosa (Quincke's edema) are more frequent. Use caution in patients with a history of peptic ulcer, in patients with a history of gastrointestinal bleeding not secondary to NSAID administration or with other bleeding disorders, in patients with Crohn's disease or ulcerative colitis, with severe liver or kidney dysfunction or heart failure. Prolonged or repeated use of products for cutaneous use can give rise to sensitization phenomena. In the presence of hypersensitivity reactions it is necessary to interrupt the therapy. Caution should be exercised when treating elderly patients who are generally more predisposed to adverse events. After a short therapy without results, consult your doctor. To avoid any hypersensitivity or photosensitization phenomena, avoid exposure to direct sunlight. Keep this medicine out of the reach and sight of children.

Expiry and Retention

This medicinal product does not require any special storage conditions.

Active principles

One patch measuring 100 x 70 mm (70 cm²) contains 14 mg of piroxicam. For the full list of excipients, see section 6.1.

Excipients

Acrylic copolymer, Eudragit E 100; non-woven fabric, silicone-coated polyester.